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For example, the likelihood of death from smallpox in an epidemic
in the pre-vaccination era was one in two and now the associated
pathogen has been eradicated, reducing the risk to zero. There are
at least 31 human diseases where significant protection can be pro-
vided by currently available vaccines. A continuing driving force in
the development and provision of effective vaccines stems from
our increased knowledge of pathogen epidemiology, and patho-
physiology and the technologies associated with the molecular
sciences. Advances in our understanding of the functioning
immune response have offered huge advantages in antigen selec-
tion, adjuvant formulation and delivery platforms for vaccines.
Ultimately, the dividend of vaccination in preventing disease
depends on the acceptance and understanding of the value brought
to society. Most importantly, vaccines are part of our armoury as a
species in fighting continuing and emerging pathogenic threats
and this battle is rarely over. Thus the benefits depend on contin-
uing immunisation and sufficient coverage of the populations at
risk. To be optimally effective a significant majority in society must
receive vaccination and this can be undermined by the actions of
vocal anti-vaccine minorities. It is vital that vaccine safety and
effectiveness are transparently and frequently reviewed; this is
necessary in order to maintain the trust and endorsement of
approval by the general public.
There are many factors that contribute to developing and deliv-
ering a vaccine and vaccination programme that can provide opti-
mal protection of at risk populations. The goal of this special issue
of Vaccine is to provide a cutting edge, comprehensive and inte-
grated perspective of the key areas from the early development
of a vaccine concept to delivery of health impact. The collection
of articles is aimed at interested research scientists and clinicians
but also the wider community of relevant health care profession-
als. The articles use specific examples of pathogens/vaccines to
illustrate the principles of development, provision including for
special populations, safety, strategies, hesitancy and impact.
The first article, Vaccine Development: From concept to early clin-
ical testing [1], covers the requirement for a detailed knowledge of
the pathogen as a pre-requisite for antigen selection. It describes
how disease epidemiology and clinical manifestations influence
vaccine requirements. Examples of how our increasing knowledge
and new technologies can drive innovative vaccine design are pro-
vided. Finally how the manufacture and delivery of vaccine anti-
gens is practicably achieved is briefly described.
The next article, Vaccine Provision: Delivering sustained & wide-
spread use [2], describes the need for extensive quality control
measures to assess vaccine safety, potency and purity. Thus a large
proportion of vaccine development time is dedicated to such qual-
ity control activities and accounts for why vaccines can take dec-ades to develop and months to produce, once approved. The
potential to expedite procedures in the face of an emergency such
as a pandemic are described. Issues such as the design of vaccine
delivery vehicles and shelf life are important. Thus single-dose
vials avoid preservatives but can significantly impact on supply
and cost. The fact that most vaccines require strict temperature
control (cold chain) also generates logistical challenges for supply
and potency.
The preeminent importance of safety is underlined in Vaccine
safety evaluation: practical aspects in assessing benefits and risks
[3]. Thus vaccine safety is assessed from inception through its
entire duration of use. A vaccine’s safety profile is continuously
updated based on continuing surveillance. When needed, actions
are taken and communicated rapidly to the community. Monitor-
ing vaccine safety is a shared responsibility and healthcare provi-
ders are encouraged to report all adverse events after
vaccination, for assessment of the cause. Verification of causality
is critical to maintaining public confidence in vaccines.
The ability to protect the most vulnerable in society through
vaccination is dealt in Vaccination of special populations: Protecting
the vulnerable [4]. Examples are given of various special groups that
are at increased risk of vaccine-preventable diseases and how vac-
cination strategies are put in place to address their disease risk. The
issues surrounding the facts that preterm infants and pregnant
women often do not receive recommended vaccines and people
with chronic medical conditions or who are immune-compromised
due to disease or aging are under-vaccinated are discussed. Ulti-
mately, national recommendation on vaccination needs to be
delivered by health providers to maximise benefits.
In this context, Vaccines Strategies: Optimizing outcomes [5],
reviews the many components that must come together for deliv-
ery of effective immunization services. This is more difficult in less
developed countries that may lack the appropriate healthcare
infrastructure. Issues covering the need for any vaccination strat-
egy to be feasible and acceptable to the target population and
how experience and research illustrate which vaccine strategies
work well are described. Thus tailored, culturally appropriate local
approaches usually encourage success.
There are increasing problems with vaccine hesitancy and this
provides a major threat to the continued prevention of known
human disease and the emerging threats for evolving or new
pathogenic threats. One key area likely to be impactful in defeating
this threat is the pivotal importance of healthcare providers in
reassuring and educating the general public and this is covered
in Vaccine hesitancy and healthcare providers [6].
Finally, Vaccine Impact: Benefits for human health [7], reviews the
broad impact of vaccines on health extending beyond the
vaccinated individual. Thus vaccines can positively impact health,
6654 Editorial / Vaccine 34 (2016) 6653–6654cognitive development and productivity. Continuing and broader
success requires delivering vaccine coverage sufficient to interrupt
transmission. It is important to note that vaccination can modify
disease epidemiology and that this will require changes in vaccine
strategies. Ultimately, ensuring the continued success of vaccina-
tion is a shared responsibility of all aspects of the global
community.
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